Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) PT at $35.83

OrthoPediatrics Corp. (NASDAQ:KIDS) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $35.83.

A number of research firms have recently weighed in on KIDS. Piper Sandler cut their price objective on shares of OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Stifel Nicolaus cut their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Lake Street Capital began coverage on OrthoPediatrics in a report on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Thursday, May 8th. Finally, Truist Financial reduced their price target on OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating for the company in a research report on Friday, April 11th.

Insider Activity at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company’s stock, valued at $7,934,193.30. The trade was a 2.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gregory A. Odle sold 5,359 shares of the business’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares of the company’s stock, valued at approximately $3,698,869.68. This trade represents a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock worth $589,978 in the last 90 days. 32.70% of the stock is owned by insiders.

Hedge Funds Weigh In On OrthoPediatrics

Several institutional investors and hedge funds have recently bought and sold shares of KIDS. Invesco Ltd. raised its holdings in OrthoPediatrics by 3.0% in the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company’s stock worth $379,000 after purchasing an additional 469 shares during the period. Northern Trust Corp increased its position in shares of OrthoPediatrics by 0.3% in the 4th quarter. Northern Trust Corp now owns 193,798 shares of the company’s stock valued at $4,492,000 after buying an additional 644 shares in the last quarter. Rhumbline Advisers raised its stake in OrthoPediatrics by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company’s stock worth $612,000 after buying an additional 1,042 shares during the period. R Squared Ltd bought a new position in OrthoPediatrics during the fourth quarter worth about $48,000. Finally, Bank of New York Mellon Corp lifted its holdings in OrthoPediatrics by 3.8% during the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company’s stock worth $1,338,000 after acquiring an additional 2,099 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Trading Up 5.6%

Shares of OrthoPediatrics stock opened at $23.27 on Thursday. OrthoPediatrics has a fifty-two week low of $20.25 and a fifty-two week high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The company has a market capitalization of $565.16 million, a P/E ratio of -18.92 and a beta of 1.09. The company has a fifty day moving average of $23.03 and a 200 day moving average of $24.05.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). The company had revenue of $52.41 million for the quarter, compared to analysts’ expectations of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. On average, sell-side analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.